Melissa Waterbury
Family · Kennewick, WANPI 1598908576
Payments from drug & device makers
Across 241 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$525
- Lilly USA, LLC$406
- Regeneron Healthcare Solutions, Inc.$214
- Arcutis Biotherapeutics, Inc.$190
- E.r. Squibb & Sons, L.L.C.$174
- plus $809 from 13 others
What the payments were for
- Food & beverage$3,32687%
- Education$49613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 114 | $1,504 |
| AbbVie | 38 | $525 |
| Lilly USA, LLC | 24 | $406 |
| Regeneron Healthcare Solutions, Inc. | 7 | $214 |
| Arcutis Biotherapeutics, Inc. | 15 | $190 |
| E.r. Squibb & Sons, L.L.C. | 5 | $174 |
| Sanofi | 4 | $114 |
| Dermavant Sciences, Inc. | 7 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Incyte Corporation | 4 | $82 |
| LEO Pharma Inc. | 4 | $80 |
| UCB, Inc. | 4 | $73 |
| Novartis | 4 | $61 |
| Merz North America, Inc. | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 3 | $48 |
| Organogenesis Inc. | 2 | $45 |
| Biofrontera Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Pfizer | 1 | $14 |
How this compares
$3,822 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $117,243 |
| Dupixent SyringeDupilumab | 11 | $48,423 |
| Tacrolimus | 23 | $13,370 |
| Clobetasol Propionate | 32 | $2,713 |
| Calcipotriene | 16 | $2,041 |
| Ketoconazole | 124 | $1,917 |
| Acitretin | 11 | $1,913 |
| Triamcinolone Acetonide | 112 | $1,752 |
| Betamethasone Dipropionate | 30 | $1,058 |
| Metronidazole | 26 | $1,029 |
| Imiquimod | 28 | $713 |
| Clindamycin Phosphate | 16 | $654 |
| NystopNystatin | 22 | $430 |
| Hydrocortisone | 20 | $408 |
| Doxycycline Hyclate | 27 | $349 |
Paid to pharmacies, not to this prescriber.
Other family in Kennewick
- Rebecca EngKennewick$7K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.